The purpose of this study is to further investigate the lead compound, Pt-Mal-LHRH, as a more specific and potent breast cancer treatment to encourage advancement into clinical trials. Pt-Mal-LHRH has already been previously reported to be cytotoxic in-vitro and attenuate breast cancer tumor size in-vivo (Calderon, et al., 2016). The next step toward clinical trials of Pt-Mal-LHRH is to confirm the drug delivery is selective towards breast cancer cells and determine the therapeutic index. Tumors were grown in the female Balb/c mice, they were injected dose dependently with 2.5 – 20 mg/kg/wk Pt-Mal-LHRH and molar equivalent doses of the carboplatin. Both the carboplatin and Pt-Mal-LHRH mice behavior was then observed and compared to a control group for any negative side effects. These effects included signs of decreased strength, movement, and lethargy. Physical effects of the compound on other organs and systems in the body were also determined through weight to body size analyses. Pt-Mal-LHRH was confirmed to be an effective treatment in which dose-dependent reduction in tumor size was found and significantly attenuated tumor growth compare to carboplatin.
Semester/Year of Award
Lindsay E. Calderon
Closed Access Thesis
Smith, Madison, "Evaluation of the Therapeutic Potential of Pt-Mal-LHRH in Attenuating Triple Negative Breast Cancer" (2017). Honors Theses. 465.